Is IBB a good investment?

iShares Biotechnology ETF (IBB) is a healthcare and biotech ETF. As of September 11, 2026, ETF Copilot scores IBB 3.1 out of 10 — highest on Risk (4.2), lowest on Growth (1.9). It trades at 22.7 times earnings, against its own median of 21.5. Its ten largest holdings are 48% of the fund.

Updated September 11, 2026

How is IBB rated? ETF Copilot scores iShares Biotechnology ETF (IBB) 3.1 out of 10

As of September 11, 2026, ETF Copilot scores iShares Biotechnology ETF (IBB) 3.1 out of 10 overall.

ETF Copilot scores (0–10 scale, higher is better):

Overall: 3.1 / 10
Growth: 1.9 / 10
Valuation: 3.5 / 10
Risk: 4.2 / 10
Quality: 3.4 / 10
Return: 3.1 / 10

What is IBB's expense ratio? 0.44% a year

As of September 11, 2026, IBB charges 0.44% a year, yields 0.46% and holds $10.7B in assets across 239 positions.

iShares Biotechnology ETF (IBB) — cost, income and size
Measure	IBB
Expense ratio	0.44%
Dividend yield	0.46%
Assets under management	$10.7B
Holdings	239

Expense ratio, dividend yield and assets under management are reported by the fund and refreshed daily. Every other figure on this page is computed by ETF Copilot.

What stands out in IBB's data

U.S. biotechnology stocks, tracked through a broad industry benchmark.

Profitability trails most peers — the industry's high research costs eat into margins.

EBITDA margin of 20.4% runs behind the category median of 21.2% and below its own five-year average of 22.4%. Pays a 0.5% dividend yield.

A broad biotech allocation that trades narrower margins for wide industry coverage.

Why did IBB move this week? It fell 5.1% in the week to September 11, 2026 — Amgen and Vertex Pharmaceuticals drove it

IBB fell 5.1% in the week to September 11, 2026. The holdings that moved it most were Amgen (−15.0%), Vertex Pharmaceuticals (−7.6%) and Regeneron Pharmaceuticals (−7.3%); Roivant Sciences (+18.6%) pushed the other way.

Is IBB expensive right now? It trades at 22.7 times earnings, against its own median of 21.5

As of September 11, 2026, IBB is more expensive than 60% of its own 114 monthly readings since 2017 — 68 of those months were cheaper than today.

Trailing twelve-month, computed by ETF Copilot from the fund's holdings rather than quoted from a data provider, and rebuilt nightly.

What's inside IBB?

What's inside IBB: Size (Large 52%, Mid 34%, Small 14%); Geography (International 15%, US 86%); AI 0.7%.

What are IBB's top holdings? The ten largest are 48% of the fund

Vertex Pharmaceuticals, Amgen, Gilead Sciences, Regeneron Pharmaceuticals, Argenx SE, Moderna, Natera, Revolution Medicines, Alnylam Pharmaceuticals and Illumina are IBB's largest holdings, in that order.

Less concentrated than 63% of Healthcare & Biotech ETFs.

Half of IBB's weight sits in its 12 largest positions, and once those weights are taken into account it behaves like 32 equally weighted holdings.

Cite this

ETF Copilot, “iShares Biotechnology ETF (IBB) scores and holdings analysis”, as of September 11, 2026.
https://etf-copilot.com/etf/ibb